Published Date:2021-12-03
Original Link:https://www.onenessbio.com/en/news_detail127_1.htm
| No | 1 | Date of announcement | 2021/12/03 | Time of announcement | 16:56:09 |
|---|---|---|---|---|---|
| Subject | The mechanism of action and Phase 3 MRCT results of the diabetic foot ulcer new drug, Fespixon have been accepted for an oral presentation at IDF Congress 2021 | ||||
| To which item it meets | paragraph 12 | Date of events | 2021/12/03 | ||
| Statement | |||||
|
1.Date of institutional investor conference:2021/12/08 2.Time of institutional investor conference:23:49 (TPE time) 3.Location of institutional investor conference:Online 4.Outline of institutional investor conference: (1)The mechanism of action and Phase 3 MRCT results of Fespixon (new drug for diabetic foot ulcers) have been accepted for an oral presentation at IDF Congress 2021 at 23:49 on 8th of December, 2021 (CET 16:49). The IDF congress this year will be held virtually due to the global pandemic of COVID-19. (2) The International Diabetes Federation (IDF) has been the most representative organization in diabetes established since 1950 and is composed of more 240 medical societies from approx. 170 countries. The IDF Congress is held once every 2 years attended by more than 12,000 physicians, scientists, nurses, educators, other healthcare professionals, government representatives, policy makers, etc. The latest progress in diabetes care, treatment, prevention and the related complications will be updated in this Congress. 5.Any other matters that need to be specified: The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation. |
|||||